Legal & General Group
AXDX

Legal & General Group’s Accelerate Diagnostics AXDX Stock Holding History

Legal & General Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,328
Closed -$62K – 3531
2022
Q1 		$62K Hold
4,328
– – ﹤0.01% 2960
2021
Q4 		$226K Buy
4,328
+2,932
+210% +$163K ﹤0.01% 2679
2021
Q3 		$82K Buy
1,396
+646
+86% +$42.1K ﹤0.01% 2890
2021
Q2 		$60K Hold
750
– – ﹤0.01% 2889
2021
Q1 		$63K Sell
750
-15
-2% -$1.52K ﹤0.01% 2750
2020
Q4 		$58K Hold
765
– – ﹤0.01% 2759
2020
Q3 		$82K Sell
765
-128
-14% -$17.8K ﹤0.01% 2541
2020
Q2 		$135K Buy
893
+43
+5% +$4.24K ﹤0.01% 2451
2020
Q1 		$71K Sell
850
-127
-13% -$17.9K ﹤0.01% 2498
2019
Q4 		$165K Buy
977
+149
+18% +$24.6K ﹤0.01% 2443
2019
Q3 		$154K Buy
828
+228
+38% +$44.1K ﹤0.01% 2411
2019
Q2 		$137K Hold
600
– – ﹤0.01% 2440
2019
Q1 		$126K Hold
600
– – ﹤0.01% 2433
2018
Q4 		$69K Buy
600
+187
+45% +$27.7K ﹤0.01% 2572
2018
Q3 		$94K Hold
413
– – ﹤0.01% 2527
2018
Q2 		$92K Sell
413
-77
-16% -$17.2K ﹤0.01% 2522
2018
Q1 		$112K Sell
490
-174
-26% -$45.7K ﹤0.01% 2452
2017
Q4 		$176K Sell
664
-42
-6% -$9.85K ﹤0.01% 2367
2017
Q3 		$158K Buy
706
+31
+5% +$7.61K ﹤0.01% 2425
2017
Q2 		$184K Buy
675
+163
+32% +$44.2K ﹤0.01% 2326
2017
Q1 		$123K Buy
512
+1
+0.2% +$228 ﹤0.01% 2440
2016
Q4 		$108K Buy
511
+121
+31% +$28.7K ﹤0.01% 2516
2016
Q3 		$104K Sell
390
-28
-7% -$6.2K ﹤0.01% 2207
2016
Q2 		$59K Hold
418
– – ﹤0.01% 2384
2016
Q1 		$59K Hold
418
– – ﹤0.01% 2334
2015
Q4 		$90K Hold
418
– – ﹤0.01% 2136
2015
Q3 		$66K Hold
418
– – ﹤0.01% 2295
2015
Q2 		$111K Hold
418
– – ﹤0.01% 2034
2015
Q1 		$95K Hold
418
– – ﹤0.01% 2075
2014
Q4 		$80K Sell
418
-34
-8% -$7.28K ﹤0.01% 2132
2014
Q3 		$91K Buy
+452
New +$87.9K ﹤0.01% 1936

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Legal & General Group's AXDX Position: Q2 2022 in Review

Legal & General Group sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 4,328 shares — an estimated $62K sold.

Legal & General Group first reported a position in AXDX in Q3 2014 and held it in 31 quarters. The position peaked at $226K in Q4 2021. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Legal & General Group reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 4,328 Accelerate Diagnostics shares in Q2 2022, an estimated $62K.
  • Legal & General Group first reported a position in Accelerate Diagnostics in Q3 2014 and held it in 31 quarters.
  • Legal & General Group's Accelerate Diagnostics position peaked at $226K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.